CONMED (CNMD)
(Delayed Data from NYSE)
$70.60 USD
-1.00 (-1.40%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $70.58 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
CONMED Corporation [CNMD]
Reports for Purchase
Showing records 441 - 460 ( 495 total )
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Vs. Our Model, 4Q Results and 2016 Guidance in Line with Expectations
Provider: KEYBANC CAPITAL MARKETS
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Morning Meeting Notes
Provider: KEYBANC CAPITAL MARKETS
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Industry: 4Q Earnings Preview; Results Likely in Line; Cautious Around 2016 Guidance
Provider: KEYBANC CAPITAL MARKETS
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Impact of Potential Government Spending Agreement on Medical Products/Life Science Tools Coverage
Provider: KEYBANC CAPITAL MARKETS
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Encouraging Next Step in the LT Turnaround Thesis, Although Cautious on NT Accretion Expectations
Provider: KEYBANC CAPITAL MARKETS
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Resetting Investor Expectations Following Earnings Miss and Guidance Revision
Provider: KEYBANC CAPITAL MARKETS
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
Company: CONMED Corporation
Industry: Medical - Dental Supplies
EPS Miss; Guidance Still Intact, but the Path Appears More Challenging
Provider: KEYBANC CAPITAL MARKETS